Clinical Trial Update: Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

Extension study results for APD334-003 in moderately to severely active ulcerative colitis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• APD334-003 (APD334-003)

Snippet

Sponsor: Arena Pharmaceuticals | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED | Results posted: 2021-11-26